<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04555317</url>
  </required_header>
  <id_info>
    <org_study_id>CFTSp180</org_study_id>
    <nct_id>NCT04555317</nct_id>
  </id_info>
  <brief_title>Bone Toxicity Following Pelvic Radiotherapy</brief_title>
  <acronym>RadBone</acronym>
  <official_title>Bone Toxicity Following Pelvic Radiotherapy: A Prospective Randomised Controlled Feasibility Study Evaluating a Musculoskeletal Health Package in Women With Gynaecological Cancers Undergoing Pelvic Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Christie NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Christie NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised controlled clinical feasibility trial to determine the feasibility and&#xD;
      acceptability of a &quot;musculoskeletal health package (MHP)&quot; intervention in women undergoing&#xD;
      pelvic radiotherapy for gynaecological malignancies and inform power calculations for a&#xD;
      definitive trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomly assigned to either an observational arm or an interventional arm consisting of a musculoskeletal health package</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eligibility and screening rate</measure>
    <time_frame>baseline</time_frame>
    <description>proportion of patients eligible for the study from the patient population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recruitment and study group allocation rate</measure>
    <time_frame>2 weeks post consent</time_frame>
    <description>number of eligible patients recruited, randomised and allocated to appropriate study populations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recruitment and study group allocation rate</measure>
    <time_frame>2 weeks post consent</time_frame>
    <description>proportion of eligible patients recruited, randomised and allocated to appropriate study populations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intervention fidelity rate</measure>
    <time_frame>end of study 18 months</time_frame>
    <description>number of patients completing the elements of the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intervention fidelity rate</measure>
    <time_frame>end of study 18 months</time_frame>
    <description>proportion of patients completing the elements of the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Attrition rate</measure>
    <time_frame>end of study 18 months</time_frame>
    <description>number of patients lost to follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient and physician acceptability y</measure>
    <time_frame>change from baseline to 6 months</time_frame>
    <description>Patient and physician acceptability assessed with electronic questionnaires</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient and physician acceptability y</measure>
    <time_frame>change from baseline to 12 months</time_frame>
    <description>Patient and physician acceptability assessed with electronic questionnaires</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient and physician acceptability y</measure>
    <time_frame>change from baseline to 18 months</time_frame>
    <description>Patient and physician acceptability assessed with electronic questionnaires</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health Economic QOL Analysis</measure>
    <time_frame>change from baseline to 6 months</time_frame>
    <description>EuroQol-5D-5L Quality of Life assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health Economic QOL Analysis</measure>
    <time_frame>change from baseline to 12 months</time_frame>
    <description>EuroQol-5D-5L Quality of Life assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health Economic QOL Analysis</measure>
    <time_frame>change from baseline to 18 months</time_frame>
    <description>EuroQol-5D-5L Quality of Life assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Radiotherapy Related Insufficiency Fracture (RRIF)</measure>
    <time_frame>assessed at 6, 12 , 18 months post radiotherapy</time_frame>
    <description>Incidence of RRIF assessed by MR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal change in BMD</measure>
    <time_frame>assessed at baseline and 18 months</time_frame>
    <description>BMD measured by DXA at baseline and 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal change in fracture risk using FRAX (inc BMD by DXA)</measure>
    <time_frame>assessed at baseline and 18 months</time_frame>
    <description>FRAX assessment tool (including femoral neck BMD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal change in biochemical markers of bone turnover (BTM)</measure>
    <time_frame>change from baseline to week 2</time_frame>
    <description>serum Bone Turnover Markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal change in biochemical markers of bone turnover (BTM)</measure>
    <time_frame>change from baseline to week 3</time_frame>
    <description>serum Bone Turnover Markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal change in biochemical markers of bone turnover (BTM)</measure>
    <time_frame>change from baseline to week 4</time_frame>
    <description>serum Bone Turnover Markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal change in biochemical markers of bone turnover (BTM)</measure>
    <time_frame>change from baseline to week 5</time_frame>
    <description>serum Bone Turnover Markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal change in biochemical markers of bone turnover (BTM)</measure>
    <time_frame>change from baseline to week 6</time_frame>
    <description>serum Bone Turnover Markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal change in biochemical markers of bone turnover (BTM)</measure>
    <time_frame>change from baseline to week 7</time_frame>
    <description>serum Bone Turnover Markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal change in biochemical markers of bone turnover (BTM)</measure>
    <time_frame>change from baseline to week 8</time_frame>
    <description>serum Bone Turnover Markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal change in biochemical markers of bone turnover (BTM)</measure>
    <time_frame>change from baseline to week 9</time_frame>
    <description>serum Bone Turnover Markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal change in biochemical markers of bone turnover (BTM)</measure>
    <time_frame>change from baseline to 6 months</time_frame>
    <description>serum Bone Turnover Markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal change in biochemical markers of bone turnover (BTM)</measure>
    <time_frame>change from baseline to 12 months</time_frame>
    <description>serum Bone Turnover Markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal change in biochemical markers of bone turnover (BTM)</measure>
    <time_frame>change from baseline to 18 months</time_frame>
    <description>serum Bone Turnover Markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessment : adapted CTCAE pelvic questionnaire</measure>
    <time_frame>change from baseline to 6 months</time_frame>
    <description>CTCAE pelvic questionnaire, (common terminology criteria for adverse events). (measures: Bowel questions scored out of 22, urinary questions out of 19 and sexual questions out of 8. Total out of 49: higher score = worse quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessment : adapted CTCAE pelvic questionnaire</measure>
    <time_frame>change from baseline to 12 months</time_frame>
    <description>CTCAE pelvic questionnaire, (common terminology criteria for adverse events). (measures: Bowel questions scored out of 22, urinary questions out of 19 and sexual questions out of 8. Total out of 49: higher score = worse quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessment : adapted CTCAE pelvic questionnaire</measure>
    <time_frame>change from baseline to 18 months</time_frame>
    <description>CTCAE pelvic questionnaire, (common terminology criteria for adverse events). (measures: Bowel questions scored out of 22, urinary questions out of 19 and sexual questions out of 8. Total out of 49: higher score = worse quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessment: SMFA adapted to lower limbs</measure>
    <time_frame>change from baseline to 6 months</time_frame>
    <description>adapted SMFA : short form musculoskeletal function assessment (scores are standardised with high scores indicating poor function. 39 questions min score possible 39, max score possible 195 (raw scores)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessment: SMFA adapted to lower limbs</measure>
    <time_frame>change from baseline to 12 months</time_frame>
    <description>adapted SMFA : short form musculoskeletal function assessment (scores are standardised with high scores indicating poor function. 39 questions min score possible 39, max score possible 195 (raw scores)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessment: SMFA adapted to lower limbs</measure>
    <time_frame>change from baseline to 18 months</time_frame>
    <description>adapted SMFA : short form musculoskeletal function assessment (scores are standardised with high scores indicating poor function. 39 questions min score possible 39, max score possible 195 (raw scores)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Gynecologic Cancer</condition>
  <condition>Radiotherapy Side Effect</condition>
  <condition>Fracture</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention. Standard of care cancer pathway followed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Musculoskeletal Health Package</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 month prehabilitation exercise program during radiotherapy and assessment of BMD at baseline with appropriate management according to fracture risk assessment (with either (a) lifestyle advice, (b) calcium and vitamin D (c) calcium, vitamin D and bisphosphonate (alendronate))</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Musculoskeletal health package</intervention_name>
    <description>3 month prehabilitation exercise program during radiotherapy with assessment of BMD at baseline with appropriate management according to fracture risk assessment (with either (a) lifestyle advice, (b) calcium and vitamin D (c) calcium, vitamin D and bisphosphonate (alendronate))</description>
    <arm_group_label>Musculoskeletal Health Package</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age over 18 years&#xD;
&#xD;
          -  histologically confirmed uterine or cervix cancer&#xD;
&#xD;
          -  patients undergoing potentially curative/adjuvant radiotherapy&#xD;
&#xD;
          -  ability to give informed consent to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age less than 18 years or greater than 85 years&#xD;
&#xD;
          -  patients with pre-existing bone conditions such as: osteoporosis treated with&#xD;
             bisphosphonates in the previous 5 years/fibrous dysplasia/osteogenesis imperfecta or&#xD;
             other metabolic bone condition&#xD;
&#xD;
          -  inability to give informed consent to participate&#xD;
&#xD;
          -  home address outside Greater Manchester&#xD;
&#xD;
          -  contraindication or intolerance of Magnetic Resonance scanning&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Gynae-oncology patients with cervical or endometrial cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 2, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2020</study_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

